Multitargeted therapies for multiple myeloma

Abstract

Multiple myeloma (MM) comprises 1% of all malignancies and 10% of all hematological malignancies. MM is a malignancy of plasma cells in the bone marrow where complex and dynamic interactions with the bone marrow microenvironment lead to tumor progression, skeletal destruction and angiogenesis. Despite the discovery of several novel treatments against MM, including the proteasome inhibitor bortezomib, it is considered to be an incurable disease with an average 4–5 years overall survival.

Keywords: :

• sorafenib
• multiple myeloma
• 5T33MM
• autophagy
• bone marrow stroma
• ABT737
• cell death
• tyrosine kinase inhibitor

This article refers to:

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.